title: [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].
abstract: BACKGROUND
  Malignant pleural mesothelioma (MPM) is an aggressive, malignant tumor of the pleural surface and is strongly associated with asbestos exposure. Incidence of MPM will reach its peak over the coming years. Most patients present with advanced tumor stages and therefore surgical options are limited.
  
  
  METHODS
  Retrospective analysis of all patients with MPM reported to the tumor centre Regensburg between January 1998 and August 2011.
  
  
  RESULTS
  A total of 118 patients (85 % male) with cytologically or histologically confirmed MPM were reported. The mean age at diagnosis was 67 years (range 45-84 years) and 65 % of patients had a history of asbestos exposure. The incidence of MPM at the tumor centre Regensburg was 0.8/100,000 inhabitants with obvious regional differences depending on asbestos exposure. Staging was completed in 81 patients (67 %): stage I 9 %, stage II 22 %, stage III 23 % and stage IV 46 %. Of the patients 87 (74 %) underwent at least one surgical procedure: diagnostic thoracoscopy with biopsy (n = 37, 43 %), debulking surgery or talcum pleurodesis (n = 33, 38 %) and potentially curative resection (n = 17, 19 %). After a mean follow-up of 20 months the overall median survival was 14 months (1 year survival rate 62 %, 3 year survival rate 15 %). Patients had a significantly better median survival of 18 months after curative resection.
  
  
  CONCLUSIONS
  The distribution of MPM varies according to regional and industrial asbestos exposure. Screening and diagnostics should concentrate on locations with higher incidence of MPM to facilitate surgical therapy in a multimodal treatment regime.
authors.affiliation: Abteilung für Thoraxchirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Deutschland, micha.ried@t-online.de.
authors.forename: M
authors.initials: M
authors.lastname: Ried
authors.forename: U
authors.initials: U
authors.lastname: Speth
authors.forename: T
authors.initials: T
authors.lastname: Potzger
authors.forename: R
authors.initials: R
authors.lastname: Neu
authors.forename: C
authors.initials: C
authors.lastname: Diez
authors.forename: M
authors.initials: M
authors.lastname: Klinkhammer-Schalke
authors.forename: H-S
authors.initials: HS
authors.lastname: Hofmann
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001195:Asbestosis / Q000150:complications; D001706:Biopsy; D002173:Cancer Care Facilities; D003430:Cross-Sectional Studies; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D010994:Pleura / Q000473:pathology / Q000601:surgery; D010997:Pleural Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018700:Pleurodesis; D011157:Population Dynamics; D012189:Retrospective Studies; D015996:Survival Rate; D013906:Thoracoscopy